Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858749 · ClinicalTrials.gov registry record
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 494
- Enrollment target
NCT05858749 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 494 participants.
The verdict
NCT05858749 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 494 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: * are 18 years old or above and have mRCC * took medicines that use the bodies immunity to fight against cancer as their first choice of treatment * took other medicines after taking the above first choice of treatment This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include: * the length of time between the start of a patient's treatment and the end of treatment * the length of time between the start of treatment and death * physician assessment of a patient's response to treatment We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2022-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05858749
The ClinicalTrials.gov registry entry for NCT05858749 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05858749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05858749 about?
NCT05858749 is a clinical study titled "A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).". The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: * are 18 years old or above and have mRCC * took medicines that use the bodies immunity to fight against cancer as ...
What is the current status of trial NCT05858749?
This trial is currently completed. The enrollment target is 494 participants. The study started on 2022-06-20. Estimated completion is 2022-11-30.
Who is sponsoring clinical trial NCT05858749?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.